Log In
Print
BCIQ
Print
Print this Print this
 

GS-5806

  Manage Alerts
Collapse Summary General Information
Company Gilead Sciences Inc.
DescriptionOral respiratory syncytial virus (RSV) fusion inhibitor
Molecular Target RSV F protein
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase II
Standard IndicationRespiratory syncytial virus (RSV)
Indication DetailsTreat respiratory syncytial virus (RSV) infection
Regulatory Designation

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today